The placement of multiple plastic stents still has important roles in candidates for chemotherapy for unresectable perihilar cholangiocarcinoma.


Journal

Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 02 03 2020
revised: 07 06 2020
accepted: 06 07 2020
pubmed: 14 8 2020
medline: 16 10 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

Placement of uncovered self-expandable metallic stents (U-SEMSs) of patients with unresectable perihilar cholangiocarcinoma (UPHC) is recommended as the treatment of first choice to address bile stasis. The aim of this study was to determine which of the following two endoscopic stents might be the stent of first choice for the treatment of biliary stasis in patients with UPHC: plastic stents (PSs) or U-SEMSs. U-SEMSs, deployed as a stent-in-stent, were selected as the stents of first choice from 2013 and 2014, while PSs began to be selected as the stents of first choice from 2015 onward. The median time to recurrent biliary obstruction were 66 days in the PS group (N = 38) and 105 days in the U-SEMS group (N = 37; P = .04). Emergency endoscopy was necessitated in 76.3% (29/38) of patients of the PS group and 54.1% (20/37) of patients of the U-SEMS group (P = .0434). The success rate of the first reintervention was 96.5% (27/29) in the PS group and 55% (11/20) in the U-SEMS group (P = .0002). Sustainable chemotherapy could be carried out in 55.2% of patients in the PS group and 32.4% of patients in the U-SEMS group (P = .0472). Multivariate analysis identified selection of U-SEMS as the stent of first choice as the only independent factor predictive of successful reintervention (P = .0016, odds ratio = 0.058). However, the stent selection was not an independent factor for feasible chemotherapy. Plastic stent placement could enhance the success rate of reintervention in patients with UPHC and might be facilitated by sustainable chemotherapy. However, stent selection might not have an influence on the prognosis.

Sections du résumé

BACKGROUND/PURPOSE OBJECTIVE
Placement of uncovered self-expandable metallic stents (U-SEMSs) of patients with unresectable perihilar cholangiocarcinoma (UPHC) is recommended as the treatment of first choice to address bile stasis. The aim of this study was to determine which of the following two endoscopic stents might be the stent of first choice for the treatment of biliary stasis in patients with UPHC: plastic stents (PSs) or U-SEMSs.
METHODS METHODS
U-SEMSs, deployed as a stent-in-stent, were selected as the stents of first choice from 2013 and 2014, while PSs began to be selected as the stents of first choice from 2015 onward.
RESULTS RESULTS
The median time to recurrent biliary obstruction were 66 days in the PS group (N = 38) and 105 days in the U-SEMS group (N = 37; P = .04). Emergency endoscopy was necessitated in 76.3% (29/38) of patients of the PS group and 54.1% (20/37) of patients of the U-SEMS group (P = .0434). The success rate of the first reintervention was 96.5% (27/29) in the PS group and 55% (11/20) in the U-SEMS group (P = .0002). Sustainable chemotherapy could be carried out in 55.2% of patients in the PS group and 32.4% of patients in the U-SEMS group (P = .0472). Multivariate analysis identified selection of U-SEMS as the stent of first choice as the only independent factor predictive of successful reintervention (P = .0016, odds ratio = 0.058). However, the stent selection was not an independent factor for feasible chemotherapy.
CONCLUSIONS CONCLUSIONS
Plastic stent placement could enhance the success rate of reintervention in patients with UPHC and might be facilitated by sustainable chemotherapy. However, stent selection might not have an influence on the prognosis.

Identifiants

pubmed: 32786134
doi: 10.1002/jhbp.804
doi:

Substances chimiques

Plastics 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-711

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2020 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Références

Kim SH, Kim IH, Kim SW. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. World J Gastroenterol. 2009;15:4593-5.
Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downstaging chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318-24.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-17.
Cassani LS, Chouhan J, Chan C, Lanke G, Chen H-C, Wang X, et al. Biliary decompression in perihilar cholangiocarcinoma improves survival: a single-center retrospective analysis. Dig Dis Sci. 2019;64:561-9.
Bithmuth H, Nakache R, Diamond T. Management strategies in resection for hilar biliary cholangiocarcinoma. Ann surg. 1992;215:31-8.
Iacono C, Ruzzenente A, Campagnaro T, Bortolasi L, Valdegamberi A, Guglielmi A. Role of preoperative biliary drainage in jaundiced patients who are candidates for pancreatoduodenectomy or hepatic resection: highlights and drawbacks. Ann Surg. 2013;257:191-204.
Valle J, Wasan H, Palmer DH, Cunninghaum D, Anthony A, Maraveyas A, et al. Cisplatin plus gemcitabin for biliary tract cancer. N Engl J Med. 2010;362:1273-81.
Lee TH, Moon JH, Choi JH, Lee SH, Lee YN, Paik WH, et al. Prospective comparison of endoscopic bilateral stent-in-stent versus stent-by-stent deployment for inoperable advanced malignant hilar biliary stricture. Gastrointest Endosc. 2019;90:222-30.
Inoue T, Okumura F, Naitoh I, Fukusada S, Kachi K, Ozeki T. Feasibility of the placement of a novel 6-mm diameter threaded fully covered self-expandable metal stent for malignant hilar biliary obstructions (with video). Gastrointest Endosc. 2016;84:352-7.
Yoshida T, Hara K, Imaoka H, Hijioka S, Mizuno N, Ishihara M, et al. Benefits of side-by-side deployment of 6-mm covered self-expandable metal stents for hilar malignant biliary obstructions. J Hepatobiliary Pancreat Sci. 2016;23:548-55.
Kubota K, Hasegawa S, Iwasaki A, Sato S, Fujita Y, Hosono K, et al. Stent placement above the sphincter of Oddi permits implementation of neoadjuvant chemotherapy in patients with initially unresectable Klatskin tumor. Endosc Int Open. 2016;04:E427-33.
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308-21.
Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 547 consecutive resections. Ann Surg. 2013;258:129-40.
Shimizu H, Kimura F, Yoshitomi H, Ohtsuka M, Kato A, Yoshitomi H, et al. Aggressive surgical resection of hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann surg. 2010;251:281-6.
Freeman ML, Selective OC. MRCP and CT-targeted drainage of malignant hilar biliary obstruction with self-expanding metallic stents. Gastrointest Endosc. 2003;58:41-9.
Caillol F, Bories E, Zemmour C, Pesenti C, Jean Philippe Ratone JP, Gilabert M, et al. Palliative endoscopic drainage of malignant stenosis of biliary confluence: efficiency of multiple drainage approach to drain a maximum of liver segments. United European Gastroenterol J. 2019;7:52-9.
Maeda T, Ebata T, Yokoyama Y, Mizuno T, Yamaguchi J, Onoue S, et al. Preoperative course of patients undergoing endoscopic nasobiliary drainage during the management of resectable perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2019;26:341-7.
Kawakami H, Itoi T. A novel integrated inside biliary stent and nasobiliary drainage catheter system for biliary drainage (with video). J Hepatobiliary Pancreat Sci. 2020;27:149-50.
Isayama H, Hamada T, Yasuda I, Itoi T, Ryozawa S, Nakai Y, et al. Tokyo criteria 2014 for transpapillary biliary stenting. Dig Endosc. 2015;27:259-64.
Itoi T, Tsuyuguchi T, Takada T, Strasberg SM, Pitt HA, Kim MH, et al. Tokyo Guideline Revision Committee. TG13 indications and techniques for biliary drainage in acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2013;20:71-80.
Boškoski I, Tringali A, Familiari P, Bove V, Landi R, Attili F, et al. A 17 years retrospective study on multiple metal stents for complex malignant hilar biliary strictures: Survival, stents patency and outcomes of re-interventions for occluded metal stents. Dig Liver Dis. 2019;51:1287-93.
Mukai T, Yasuda I, Nakashima M, Doi S, Iwashita T, Iwata K, et al. Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures: a randomized controlled trial. J Hepatobiliary Pancreat Sci. 2013;20(2):214-22.
Minaga K, Takenaka M, Kitano M, Chiba Y, Imai H, Yamao K, et al. Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. Surg Endosc. 2017;31:4764-72.
Inoue T, Ibusuki M, Kitano R, Kobayashi Y, Ohashi T, Nakade Y, et al. Combined side-by-side and stent-in-stent method for triple metal stenting in patients with malignant hilar biliary obstruction. Dig Endosc. 2019;31:698-705.
Zhang JX, Liu J, Wang B, Liu S, Zu QQ, Shin HB. Retrospective comparison of different percutaneous approaches to manage occluded primary uncovered self-expandable metal stents in patients with unresectable malignant hilar biliary obstruction. Scand J Gastroenterol. 2019;54:1397-402.
Kongkam P, Tasneem AA, Rerknimitr R. Combination of endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography-guided biliary drainage in malignant hilar biliary obstruction. Dig Endosc. 2019;31:50-4.
Kanno Y, Ito K, Koshita S, Ogawa T, Masu K, Kusunose H. EUS-guided biliary drainage for malignant perihilar biliary strictures after further transpapillary intervention has been judged to be impossible or ineffective. Intern Med. 2017;56:3145-51.
Shiomi H, Matsumoto K, Isayama H. Management of acute cholangitis as a result of occlusion from a self-expandable metallic stent in patients with malignant distal and hilar biliary obstructions. Dig Endosc. 2017;29:88-93.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9.

Auteurs

Akito Iwasaki (A)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Kensuke Kubota (K)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Yusuke Kurita (Y)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Sho Hasegawa (S)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Yuji Fujita (Y)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Koji Kagawa (K)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Shingo Kato (S)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Yusuke Sekino (Y)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Kunihiro Hosono (K)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Atsushi Nakajima (A)

Department of Gastroenterology, Hepatology, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH